Seeking Alpha

Profound Medical Announces First Commercial BPH Patient Treatment Using TULSA-PRO® with TULSA-AI® Volume Reduction

TORONTO, June 10, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (PROF) (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets ...
The Manila Times

Mount Sinai Becomes First in Metro New York to Deliver Incision-Free, MRI-Guided Prostate Treatment with TULSA-PRO®

Mount Sinai advances prostate care with AI-powered therapy designed to preserve continence and sexual function ...
FierceBiotech

Profound Medical’s CEO discusses the potential of TULSA-PRO for prostate disease treatment

Arun Menawat, CEO of Profound Medical, talks about the company’s innovative TULSA-PRO technology. In a recent interview, Arun Menawat, CEO of Profound Medical, discussed the company’s innovative TULSA ...
Seeking Alpha

Flagship Pioneering and ProFound Therapeutics Announce Agreement to Identify Novel First-in-Class Therapeutics for the Treatment of Obesity under Strategic Partnership with Pfizer

CAMBRIDGE, Mass., June 12, 2024 /PRNewswire/ -- Flagship Pioneering and ProFound™ Therapeutics, a Flagship-founded company pioneering the expanded human proteome to develop novel medicines for a ...
Insider Monkey

Profound Medical Completes First Commercial BPH Treatment With New TULSA-AI Volume Reduction Module

Profound Medical Corp. (NASDAQ:PROF) is one of the best Canadian stocks with huge upside potential. On June 10, Profound Medical announced the successful completion of the first commercial benign ...